Profile data is unavailable for this security.
About the company
ENERGENESIS BIOMEDICAL CO., LTD. is mainly engaged in the research and development of new drugs. The Company's main product projects include experimental service analysis and reagent sales. The Company's main new drugs include ENERGI-F703, ENERGI-F701, ENERGI-F711, and ENERGI-F706. The ENERGI-F703 indications are diabetic foot ulcers. The ENERGI-F701 indications are abnormal alopecia. The ENERGI-F711 indications are burns. The ENERGI-F706 indications are cachexia.
- Revenue in TWD (TTM)6.78m
- Net income in TWD-199.00m
- Incorporated2012
- Employees--
- LocationEnergenesis Biomedical Co Ltd6F-3, No.21, Lane 583, Ruiguang RoadTAIPEI 114TaiwanTWN
- Phone+886 226270835
- Fax+886 226270836
- Websitehttp://www.energenesis-biomedical.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Energenesis Biomedical Co Ltd | 6.78m | -199.00m | 3.97bn | -- | -- | 5.47 | -- | 585.91 | -2.61 | -2.61 | 0.0891 | 9.53 | 0.008 | 2.69 | 7.84 | -- | -23.36 | -25.02 | -24.32 | -25.78 | 73.90 | 69.19 | -2,936.00 | -2,619.68 | 26.74 | -- | 0.0112 | -- | -2.63 | 9.01 | 1.99 | -- | -20.91 | -- |
| Unicocell Biomed Co Ltd | 19.04m | -108.55m | 4.58bn | -- | -- | 6.36 | -- | 240.46 | -1.94 | -1.94 | 0.3395 | 12.32 | 0.0247 | 1.25 | 17.87 | -- | -14.06 | -24.25 | -14.42 | -25.60 | 66.09 | 69.89 | -570.24 | -705.40 | 29.58 | -- | 0.0902 | -- | 70.79 | 34.96 | 7.73 | -- | 9.00 | -- |
| Pell Bio Med Technology Co Ltd | 17.99m | -403.74m | 4.63bn | -- | -- | 3.41 | -- | 257.50 | -8.02 | -8.02 | 0.341 | 23.77 | 0.0132 | 10.43 | 4.23 | -- | -29.90 | -- | -34.86 | -- | -113.22 | -- | -2,262.16 | -- | 7.19 | -- | 0.0985 | -- | 5.11 | -- | -73.27 | -- | -- | -- |
Data as of Sep 20 2024. Currency figures normalised to Energenesis Biomedical Co Ltd's reporting currency: Taiwan Dollar TWD
0.10%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| SSgA Funds Management, Inc.as of 05 Sep 2024 | 73.13k | 0.10% |
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
